An Australian stem cell and regenerative medicine company

November 03, 2023

Dr Kilian Kelly speaks to Ausbiz re aGVHD in the US

Following the completion of the site initiation visit at Weill Cornell Medical Center in New York for the Phase 2 clinical trial of CYP-001 in High-Risk acute Graft versus Host Disease (HR-aGvHD), Dr Kilian Kelly sat down with Ausbiz to explain what this means.

Watch the interview here